MedTrace Logo

Safety Study for NST-001 and the Neuroject Injection Set to Treat Tinnitus

NCT00957788 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2013-04-22

No results posted yet for this study

Summary

This research study involves an experimental drug (NST\_001) and a delivery system. The main purpose of this research study is to investigate the safety of NST-001, delivered directly to the inner ear for the treatment of tinnitus.

Conditions

  • Tinnitus

Interventions

DRUG

NST-001

Comparison of different dosages of drug.

Sponsors & Collaborators

  • NeuroSystec Corporation

    lead INDUSTRY

Principal Investigators

  • Bruno Frachet, MD · Hôpital Avicenne

  • Pierre Garin, MD · Cliniques Universitaries U.C.L.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • Belgium
  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00957788 on ClinicalTrials.gov